In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds

Aspasia Katragkou; Matthew McCarthy; Joseph Meletiadis; Vidmantas Petraitis; Patriss W Moradi; Gittel E Strauss; Monique M Fouant; Laura L Kovanda; Ruta Petraitiene; Emmanuel Roilides; Thomas J Walsh

doi:10.1128/AAC.03261-14

In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds

Antimicrob Agents Chemother. 2014 Nov;58(11):6934-7. doi: 10.1128/AAC.03261-14. Epub 2014 Aug 18.

Affiliations

¹ Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weil Cornell Medical Center of Cornell University, New York, New York, USA.
² Clinical Microbiology Laboratory, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
³ Astellas Pharma Global Development, Inc., Northbrook, Illinois, USA.
⁴ Infectious Disease Unit, 3rd Department of Pediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, Hippokration Hospital, Thessaloniki, Greece.
⁵ Transplantation-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weil Cornell Medical Center of Cornell University, New York, New York, USA Department of Pediatrics, Weill Cornell Medical College of Cornell University, New York, New York, USA Department of Microbiology and Immunology, Weill Cornell Medical College of Cornell University, New York, New York, USA thw2003@med.cornell.edu.

Abstract

Whether isavuconazole, an extended-spectrum triazole, possesses synergistic activity in combination therapy with echinocandins or amphotericin B for the treatment of invasive molds infections has not been studied. Our in vitro combination studies showed that isavuconazole and micafungin are synergistically active against Aspergillus fumigatus, Aspergillus flavus, Aspergillus terreus, and Cunninghamella bertholletiae. These results suggest that isavuconazole, in combination with micafungin, may have a role in the treatment of invasive aspergillosis and warrants further investigation.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Amphotericin B / pharmacology*
Antifungal Agents / pharmacology
Aspergillosis / drug therapy
Aspergillosis / microbiology
Aspergillus / drug effects*
Cunninghamella / drug effects*
Deoxycholic Acid / pharmacology*
Drug Combinations
Drug Interactions
Echinocandins / pharmacology*
Lipopeptides / pharmacology*
Micafungin
Microbial Sensitivity Tests
Mucormycosis / drug therapy
Nitriles / pharmacology*
Pyridines / pharmacology*
Triazoles / pharmacology*

Substances

Antifungal Agents
Drug Combinations
Echinocandins
Lipopeptides
Nitriles
Pyridines
Triazoles
Deoxycholic Acid
isavuconazole
Amphotericin B
amphotericin B, deoxycholate drug combination
Micafungin

Grants and funding

T32 AI007613/AI/NIAID NIH HHS/United States